Skip to content

Clinical Observation of Exosomes in Patients After Q-switched Laser Surgery

Clinical Observation of Exosomes in Patients After Q-switched Laser Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06279039
Enrollment
38
Registered
2024-02-26
Start date
2022-09-01
Completion date
2024-12-31
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Exosome, Laser, Skin Regeneration

Keywords

Exosome, Q-switched laser

Brief summary

the goal of this half-face controlled study is to evaluate the effect of exosome-containing liquid dressings on the recovery of patients after Nd:YAG laser 532 treatment.

Detailed description

The main objective was to collect patients with fleae or seborrheic keratosis after Q-switched laser treatment, and then to use exosomes or matrix on both sides of the face, and finally to evaluate the effect of exosomes on wound healing and prevention of post-inflammatory hyperpigmentation after Nd:YAG laser 532 treatment

Interventions

DRUGExosome liquid dressing

This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.

Sponsors

Nanjing First Hospital, Nanjing Medical University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* It meets the diagnostic criteria of seborrheic keratosis or freckle; * pepole are able to follow the treatment rules of the study and were followed up for 8 weeks; * informed consent

Exclusion criteria

* History of keloids ; * Pregnancy or lactation; * Any cosmetics containing growth factor-related ingredients used within 6 months prior to treatment * Patients with incomplete observation data and incomplete course of treatment were excluded

Design outcomes

Primary

MeasureTime frameDescription
Global Aesthetic Improvement Scale score1, 3.5, 7, 14, 28, and 56 daysThe treating physician evaluated the patient's improvement, which was divided into four levels: very improved corresponding, substantial improvement, improvement, no change; Corresponding to the best beauty results, significantly improved but not the best, significantly improved, no change
Dermatology Quality of life index1, 3.5, 7, 14, 28, and 56 daysBy answering multiple questions, patients self-rated the impact of their current illness on their lives within a week and scored. The answers were graded on four levels, very serious 3, very serious 2, a little 1, and no 0

Secondary

MeasureTime frameDescription
post-inflammatory hyperpigmentation2.4,8 weeksAt 2, 4 and 8 weeks of follow-up, melanin index was measured by memetreter (memetreter MX18 cuttometer Dual MPA580, EnviroDerm Services (UK) Ltd) at the same follow-up. Objective evaluation of PIH.

Countries

China

Contacts

Primary Contactjie Dai
karry_dj@126.com02552271117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026